Want to see RZLT full AI Analyst Report?
RZLT Stock Chart & Stats
$3.46
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.46
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)2.35M
Market Cap
$493.98M
Enterprise Value$451.12M
Total Cash (Recent Filing)$120.27M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Sep 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume2,318,773
30 Day Avg. Volume2,353,181
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.61K
Enterprise Value/Ebitda-5.54
Forecast
1Y Price Target
$8.43Price Target Upside143.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$3.22M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 UpLIFT Interim EfficacyRobust interim Phase 3 signals in a severe, rare indication indicate clinical efficacy and tolerability for ersodetug. Durable efficacy and safety in a pivotal setting materially reduce clinical development risk, strengthen regulatory discussions, and improve the program's long-term approval and commercial potential.
Constructive FDA Engagement On SunRIZE DataActive, clarifying dialogue with the FDA provides a structured regulatory path rather than a binary surprise. Receiving guidance and a request for comprehensive submission lets management address endpoints and datasets, lowering regulatory execution risk and improving the probability of an approvable package over months.
Conservatively Levered Balance Sheet (very Low Debt)Minimal financial leverage reduces refinancing and interest-rate pressures, preserving strategic flexibility to pursue trials, partnerships, or milestone-based financings. Low debt supports longer-term operational optionality and reduces near-term insolvency risk while development milestones are pursued.
Bears Say
No Product Revenue; Widening Net LossesAbsence of recurring revenue means ongoing operations depend on external financing. Widening net losses signal increasing cash needs to support trials and commercialization plans, heightening dilution and execution risk if capital markets or partnerships are constrained over the next several quarters.
Accelerating Negative Free Cash Flow / Cash BurnRapidly increasing free cash outflows erode runway and force near-term fundraising or partnership dependence. Persistent negative operating cash flow limits ability to expand programs concurrently and raises the probability of dilutive capital raises that can sap shareholder value and constrain long-term strategy execution.
Deeply Negative Returns On Equity And Eroded Equity BaseHighly negative ROE and declining equity indicate capital consumption rather than value creation, reducing investor confidence and making future non-dilutive funding harder to secure. Poor capital efficiency may limit strategic options and raise the cost of capital for subsequent development stages.
Rezolute News
RZLT FAQ
What was Rezolute, Inc.’s price range in the past 12 months?
Rezolute, Inc. lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute, Inc.’s market cap?
Rezolute, Inc.’s market cap is $493.98M.
When is Rezolute, Inc.’s upcoming earnings report date?
Rezolute, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 61 days.
How were Rezolute, Inc.’s earnings last quarter?
Rezolute, Inc. released its earnings results on May 12, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.181 by $0.021.
Is Rezolute, Inc. overvalued?
According to Wall Street analysts Rezolute, Inc.’s price is currently Undervalued.
Does Rezolute, Inc. pay dividends?
Rezolute, Inc. does not currently pay dividends.
What is Rezolute, Inc.’s EPS estimate?
Rezolute, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Rezolute, Inc. have?
Rezolute, Inc. has 96,292,330 shares outstanding.
What happened to Rezolute, Inc.’s price movement after its last earnings report?
Rezolute, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.181. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Rezolute, Inc.?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.43 (143.60% Upside)
$8.43 (143.60% Upside)
Blogger Sentiment
Neutral
RZLT Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 137.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.84%
12-Months-Change
Fundamentals
Return on Equity
-58.82%
Trailing 12-Months
Asset Growth
32.43%
Trailing 12-Months
Company Description
Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$8.43
▲(143.60% Upside)
Technical Analysis
Ownership Overview
10.87% Insiders
30.62% Mutual Funds
33.54% Other Institutional Investors
14.74% Public Companies and
Individual Investors